Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease.

Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study.